ClinicalTrials.gg
RecruitingNCT06166407Updated Oct 27, 2026

Breisgau PHENO-HEART MI

An observational study in Myocardial Infarction, STEMI and NSTEMI, sponsored by University Hospital Freiburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University Hospital Freiburg · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 27, 2026Now RecruitingFirst site in Germany+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 159 studies in Myocardial Infarction with a site in Germany — 13 open to participants now, 17 under way, 5 of them phase 3. Myocardial Infarction · Germany.

Planned enrollment
31st of 51
400 · median 750
Started
2025
with 1 other
Observational
52 of 159
5 open now
Primary completion
2028-04
later than 10 of 16 live
Registered
150th of 159
by date

Among the 159 studies in Myocardial Infarction with a site in Germany, this one is the 31st largest by planned enrollment of the 51 observational ones that give a count, is one of 2 that started in 2025, is one of 52 observational ones, reaches primary completion later than 10 of the 16 other live ones, and was the 150th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

13 of the 159 studies in Myocardial Infarction with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies in Myocardial Infarction with a site in Germany, or all of them as a file.
02

Study summary

Coronary heart disease and its acute complication, myocardial infarction (MI), represent the leading causes of death in Europe and the United States. Although novel treatment strategies have helped to improve survival in patients with MI, a large proportion of patients develops heart failure and is at risk of life-threatening arrhythmias. Complications arising after MI constitute a severe burden not only for the patients themselves, but also for health care systems worldwide.

The likelihood of these complications depends on the area of myocardial tissue lost and the process of myocardial repair and scar tissue formation after MI ('remodeling') which are modified by the local and systemic immune response after MI. The immune response is critical after myocardial infarction. In particular, sustained overactive and prolonged inflammatory reactions lead to accentuated myocardial damage and dysfunction. Important mediators of the inflammatory reaction after MI are monocytes, T-cells, B-cells and hematopoietic stem and progenitor cells. Following MI, myeloid cells derived from the hematopoietic system drive a sharp increase in systemic leukocyte levels that correlates closely with mortality. T- and B-cells in particular act in response to specific antigens. Most of the data regarding the inflammatory response after MI, however, are derived from animal models. The immunological phenotypes after MI and their association with clinical outcome in humans are insufficiently characterized.

Aims: The aim of this project is to provide establish clinically and immunologically well-characterized cohort of patients after MI This will aid in identifying novel prognostic cellular and humoral biomarkers that may be used to identify patients at a high inflammatory and immune risk and to guide clinical management. Furthermore, these mediators, in the future, may be targeted by novel antigen-specific immunomodulatory approaches.

Patients with myocardial infarction (STEMI and NSTEMI) will be recruited after PCI within 24h and receive a structured follow-up. Clinical read-outs include a detailed and standardized patient history, clinical examination, standard blood work, coronary angiography, ECG, echocardiography and for subgroups, MRI. Patients will present for study visits at 6 weeks, 3 months and 12 months after the initial event. Blood will be sampled at the inclusion and during follow-up visits. Peripheral blood mononuclear cells and plasma will be stored at the Cardiovascular BioBank (CVBB) and FREEZE, both institutions at the University Hospital in Freiburg. Major adverse cardiac events (myocardial infarction, stroke, hospitalization for heart failure, cardiovascular death) will be recorded using telephone interviews and standardized queries to the local authorities. Several laboratory read-outs are planned including flow cytometry, mass cytometry, single cell RNA sequencing, T cell and B cell receptor sequencing and bulk-RNA-sequencing. In an initial approach we aim to recruit 400 patients with MI, of which we expect ≈40 to develop ischemic cardiomyopathy. Differences in immunological profiles between patients that develop MI and a propensity-matched control group will then be analyzed and correlated with clinical outcome data.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with STEMI and NSTEMI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Emergency coronary angiography and age>18 years and STEMI or NSTEMI or "none of these diseases"

Exclusion criteria

Exclusion Criteria:

  • \<7,0 g/dl
  • \<50.000/µl
  • Unable to provide written
  • Age > 80 years
  • hematological neoplasia
  • metastasized cancers
  • acute infection (z.B. Sepsis)
  • Chronic Inflammatory conditions (z.B. inflammatory bowel disease, Rheumatoid arthritis, chronisch hepatitis)
  • Pregnancy
  • Resuscitation >5 min oder mehr als 1x Defibrillation vor Koronarangiographie
  • Cardiogenic shock
  • Mechanical circulatory support
  • Cardiomyopathy with an F \<40% before the event
  • Dialysis
  • Cirrhosis > CHILD-A
  • Not living in the county of Breisgau-Hochschwarzwald or Emmendingen oder planned relocation
  • Alcohol and drug abuse
  • Non-compliance
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Major adverse cardiac events

    composite endpoint of Stroke, MI, hospitalization for heart failure, cardiovascular death, revascularization

    Time frame: years

Secondary outcomes

  1. Diagnosis of atrial fibrillation

    Atrial fibrillation diagnosis by 12-lead ECG

    Time frame: years

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiology and Angiology, Medical Center - University of Freiburg
    Freiburg im Breisgau, 79106, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2028, 35 months after the start.

Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 35 months is below that.

Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Apr 2024 → May 2025 and primary completion Apr 2026 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2023
First posted
Dec 12, 2023
StartActual
May 15, 2025was Apr 2024
Primary completionEst.
Apr 15, 2028was Apr 2026
CompletionEst.
Apr 15, 2034
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
1 site added — first site in Germany
Show site
  • Department of Cardiology and Angiology, Medical Center - University of Freiburg · Freiburg im Breisgau, Germany
Oct 27, 2026
Start date
Apr 2024→May 15, 2025 (actual)
Oct 27, 2026
Primary completion
Apr 2026→Apr 15, 2028
Oct 27, 2026
Title
Breisgau Pheno Heart StudyPHENO-HEART MI
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Germany
    Show site
    • Department of Cardiology and Angiology, Medical Center - University of Freiburg · Freiburg im Breisgau, Germany
    Start date Apr 2024→May 15, 2025 (now actual)
    Primary completion Apr 2026→Apr 15, 2028
    Title Breisgau Pheno Heart StudyPHENO-HEART MI
    + 3 other changes: index terms, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06166407
Lead sponsor
University Hospital Freiburg
Responsible party
Patrick Siegel, MD (MD, University Hospital Freiburg) — Principal investigator
First posted
Dec 12, 2023
Start date
May 15, 2025
Primary completion
Apr 15, 2028 (estimated)
Completion
Apr 15, 2034 (estimated)
Last update
Oct 27, 2026

Study contacts

Patrick M Siegel, MD
Contact
patrick.siegel@uniklinik-freiburg.de
+49-761-270-34010

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion